Hybridan Small Cap Feast - 18 Jan 23

18 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Morning Note – 18 January 2023

Morning Note – 6 January 2023

Hybridan Small Cap Feast 24/11/2022

Dish of the day Joiners: One Health Group plc (AQSE: OHGR), joins the Apex segment of the AQSE Growth Market. The group provides medical services, in the form of elective surgical care, to support the NHS in the management of patients, through a growing network of community-based outreach clinics and independent hospitals. Market Cap on admission £15.05m. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Kistos Holdings plc, intends to join AIM. The Company was incorporated to act

Morning Note – 24 November 2022

Omega Diagnostics - Interims – successful transformation well underway

Interim results to 30 September continue to demonstrate the successful transformation of ODG into a solidly growing revenue and profit-generating Diagnostics business focused on Health & Nutrition. We make small reductions to our FY23E and 24E revenue and adjusted EBITDA forecasts to reflect the US investment timing, but our target price of 12p per share is unchanged. With net cash now equating to over two-thirds of the Group’s market value, the stock has a biotech rating despite growing revenue

Morning Note – 14 November 2022

Omega Diagnostics - AGM statement – FY 2023 expectations unchanged

At today’s AGM, the company reiterated its confidence in meeting FY 2023 market expectations, despite a previously identified H2 bias (67% of sales), which should benefit from a c.£0.6m order from China, stronger-than-expected growth from CNS and delayed customer orders for FoodPrint, following re-registrations in May 2022. We leave forecasts unchanged and reiterate our target price of 12p – the stock is currently trading at forecast year-end cash and should benefit from confirmation that the co

Morning Note – 5 October 2022

Morning Note – 12 September 2022

Omega Diagnostics - FY 2022 finals; new forecasts to reflect CD4 sale

Full-year results to 31 March 2022 evidence the improvement in the remaining Health & Nutrition business, unencumbered by the non-core business losses, which are included as a discontinued line item at the bottom of the P&L. Revenues for H&N were in line with the April trading update and subsequent May fundraise, rising 25% to £8.5m, with year-end net cash of £1.5m. The recent sale of the loss-making (c.£0.3m per month) CD4 business for up to £6.1m (£4m held in escrow and expected to be released

Morning Note – 3 August 2022

Hybridan Small Cap Feast 11/07/22

iners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen? Georgina Energy, an early-stage resource company with a strategy of actively pursuing the exploration, commercial development and monetisation of helium, hydrogen and hydrocarbon interests located in the Amadeus and Officer Basins in Northern and Western Australia intends to join AIM. Georgina Energy has two principal onshore interests. The first, the Mount Winter Prospect is located in the Amadeus Basin in No

Hybridan Small Cap Feast 04/07/2022

Joiners: Re-admission of 888 Holdings to the Main Market following the reverse takeover of William Hill. Leavers: Umuthi Healthcare Solutions has left the Main Market. What’s cooking in the IPO kitchen? Immediate acquisitions (IME.L) is to re-join AIM via a Reverse Takeover of Fiinu Holdings Limited. Once complete the Company is proposing to change its name to Fiinu Group plc. Fiinu intends to be a provider of a consumer banking product, the Plugin Overdraft ®, which is designed to provide custo

Morning Note – 4 July 2022

Capital raise completed – Opportunity knocks

Yourgene has raised £7.3m via a heavily discounted capital raise to support working capital and facilitate further cost saving measures. Additional sources of capital are being actively pursued, which would further strengthen the balance sheet. With the balance sheet position improving and growth in the core business returning, the cost base is being rightsized to deliver profitable growth. The pipeline of opportunities remains strong, with the principal challenge remaining converting these in a

Hybridan Small Cap Feast - 11 Jan 23

11 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Hybridan Small Cap Feast - 25 Jan 23

25 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Hybridan Small Cap Feast - 17 Jan 23

17 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

LIBERUM: Medica Group PLC* - In line statement adds assurance

Confirming further upgrades post positive update

At the trading update earlier this week, NIOX indicated FY22 EBITDA would be around £7.0m, ~15% ahead of already upgraded expectations, with net cash coming in at £19.4m. This was driven by 15% underlying revenue growth, improved gross margins on mix and ongoing operational efficiencies. We formally update our estimates in this note, increasing our FY22 PBT/EPS forecast by 20% but, prudently, leaving FY23/24 unchanged for now. The outlook remains positive with latent growth potential in the US a

Hybridan Small Cap Feast - 23 Jan 23

23 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Morning Note – 16 January 2023

Hybridan Small Cap Feast - 19 Jan 23

19 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

SHORE CAPITAL - Oxford BioDynamics+ (OBD) - House Stock at 15p

Hybridan Small Cap Feast - 20 Jan 23

20 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

FY22 update – revenues ahead of expectations

SUN continues to recover well, with increased market share in the UK and a strong pipeline of opportunities Internationally leaving the group well-placed for growth in 2023. FY22 revenues were some 5% ahead of expectations and up 20% YoY, back above pre-pandemic levels. Residual staff, supply chain and regulatory challenges should ease over the course of the year and we see grounds for increasing optimism as the year progresses. We nudge up our revenue forecasts by 5%, now forecasting a small PB

Hybridan Small Cap Feast - 26 Jan 23

26 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Cenkos: RUA Life Sciences Plc -- Vascular graft distribution agreement

RUA Life Sciences has signed a global distribution agreement with Corcym, a medical device company focussed on treating heart conditions. The agreement will cover the distribution of RUA's large bore straight and aortic root grafts, for which RUA is currently working towards gaining FDA clearance. We expect RUA's grafts to be complementary to Corcym's existing product portfolio which is sold in over 100 countries. The agreement establishes global distribution for the vascular grafts and validate

Successful completion of POLB 001 LPS challenge trial

POLB announces today that it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. Importantly POLB was safe and well tolerated and the team will be able to use this dataset as part of their discussions with potential partners at the annual JPMorgan Conference in January 2023. The full read out of